Clinical Trials Logo

Radiation Toxicity clinical trials

View clinical trials related to Radiation Toxicity.

Filter by:

NCT ID: NCT00003580 Completed - Clinical trials for Head and Neck Cancer

Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer

Start date: June 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Drugs such as amifostine may protect normal cells from the side effects of chemotherapy and radiation therapy. PURPOSE: Phase II trial to study the effectiveness of amifostine in treating side effects of treatment in patients receiving radiation therapy and cisplatin for advanced head and neck cancer.

NCT ID: NCT00003313 Completed - Lung Cancer Clinical Trials

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

Start date: September 1998
Phase: Phase 3
Study type: Interventional

RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine for non-small cell lung cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of amifostine in treating patients who have stage II or stage III non-small cell lung cancer that cannot be surgically removed and who are undergoing chemotherapy and radiation therapy.

NCT ID: NCT00003307 Completed - Prostate Cancer Clinical Trials

Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer

Start date: March 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Amifostine may protect normal cells from the side effects of radiation therapy. PURPOSE: Phase II trial to study the effectiveness of radiation therapy plus amifostine in treating patients with primary prostate cancer.